Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$10.5 - $14.2 $36,750 - $49,700
-3,500 Reduced 59.32%
2,400 $0
Q3 2022

Oct 25, 2022

SELL
$10.79 - $14.81 $29,132 - $39,987
-2,700 Reduced 31.4%
5,900 $1,000
Q2 2022

Aug 04, 2022

SELL
$7.89 - $17.88 $165,690 - $375,480
-21,000 Reduced 70.95%
8,600 $1,000
Q1 2022

Apr 14, 2022

BUY
$11.56 - $19.76 $194,208 - $331,968
16,800 Added 131.25%
29,600 $15,000
Q4 2021

Jan 18, 2022

SELL
$11.18 - $15.46 $6,708 - $9,276
-600 Reduced 4.48%
12,800 $6,000
Q3 2021

Oct 26, 2021

BUY
$14.21 - $17.65 $21,315 - $26,474
1,500 Added 12.61%
13,400 $7,000
Q2 2021

Jul 19, 2021

BUY
$9.5 - $17.24 $113,050 - $205,155
11,900 New
11,900 $5,000
Q3 2020

Oct 27, 2020

SELL
$3.43 - $5.53 $51,793 - $83,503
-15,100 Closed
0 $0
Q2 2020

Jul 22, 2020

BUY
$1.9 - $5.61 $28,690 - $84,711
15,100 New
15,100 $13,000
Q3 2019

Oct 28, 2019

SELL
$2.5 - $3.73 $4,750 - $7,087
-1,900 Closed
0 $0
Q2 2019

Aug 09, 2019

SELL
$2.91 - $9.15 $291 - $915
-100 Reduced 5.0%
1,900 $0
Q1 2019

May 10, 2019

SELL
$7.38 - $9.72 $66,420 - $87,480
-9,000 Reduced 81.82%
2,000 $5,000
Q4 2018

Feb 05, 2019

BUY
$6.51 - $9.6 $25,389 - $37,440
3,900 Added 54.93%
11,000 $9,000
Q3 2018

Nov 07, 2018

BUY
$5.52 - $7.99 $35,328 - $51,136
6,400 Added 914.29%
7,100 $6,000
Q2 2018

Aug 10, 2018

SELL
$4.6 - $6.52 $459 - $652
-100 Reduced 12.5%
700 $0
Q1 2018

May 11, 2018

SELL
$4.35 - $5.82 $434 - $582
-100 Reduced 11.11%
800 $0
Q4 2017

Jan 17, 2018

SELL
$4.16 - $5.33 $42,016 - $53,833
-10,100 Reduced 91.82%
900 $0
Q3 2017

Oct 17, 2017

BUY
$4.1 - $5.97 $45,099 - $65,670
11,000
11,000 $4,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.